Yijing Capital is an investment company established in 2015 and headquartered in Shanghai, China, with regional offices in Beijing, Hong Kong, Singapore, and Sydney. As a sister company of Yizhou Group, which ranks among China's Top 500 companies, Yijing Capital leverages decades of experience across various industries. The firm primarily focuses on the medical and health-care sector, as well as smart manufacturing, and aims to identify opportunities in high-growth industries. Yijing Capital operates multiple investment platforms and engages in equity investments using both proprietary and externally sourced funds. The company's core team possesses extensive operational and managerial expertise, enabling them to undertake a diverse range of investment projects both domestically and internationally, including sectors such as artificial intelligence, new retail, education, and new energy. Yijing Capital has successfully completed numerous investments, with several portfolio companies achieving significant growth and some going public, while also realizing substantial returns from strategic exits.
Vertaxi which develops and manufactures electric vertical takeoff and landing (eVTOL) aircraft.
Phomera
Series A in 2024
Phomera, operating under Guangyu Technology, is a high-tech enterprise focused on the research, development, and industrialization of photonic crystal metamaterials. The company specializes in creating flexible metamaterials with unique functionalities, including sound tuning, electrical conductivity, magnetic control, and color changing. Phomera aims to deliver industry-specific solutions through advanced inverse calculation and structural design techniques. Its products find applications across various sectors, including anti-counterfeiting, sensing, indication and protection, identification, and camouflage.
Arnatar Therapeutics
Series A in 2024
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Kangpu Biopharmaceuticals
Series B in 2023
Kangpu Biopharmaceuticals is a clinical-stage company dedicated to the discovery and development of small molecule drugs aimed at treating cancer, autoimmune diseases, and inflammatory disorders. The company leverages proprietary technologies that focus on the modulation of ubiquitin-protein interactions to create innovative medical treatments. Additionally, Kangpu employs a drug discovery platform known as X-Synergy®, which enhances its capabilities in developing targeted therapies. By utilizing novel approaches such as targeted protein ubiquitination and degradation, Kangpu aims to deliver effective medical solutions that improve patient health outcomes.
Taichu Biotechnology
Series A in 2023
Taichu Biotechnology is a biopharmaceutical company that specializes in providing customized technical services across the entire industry chain, focusing on both contract research organization (CRO) and contract development and manufacturing organization (CDMO) activities. The company offers a comprehensive range of services, including non-clinical drugability evaluations, antibody drug development, and production, as well as the research and development of chemical preparations. By catering to both single and combined business sectors, Taichu Biotechnology aims to support the research and development and manufacturing of various novel pharmaceuticals, ensuring tailored solutions to meet the specific needs of its clients in the biomedicine field.
NowYonMedical
Venture Round in 2023
NowYonMedical specializes in the production of medical device products. It also offers technical consulting, health management, and technology research in the field of life sciences.
Bivision
Seed Round in 2022
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Tasogare
Series C in 2022
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
Leisen Electronic Technology
Venture Round in 2022
Leisen performs R&D of industry-leading radar technologies and products for solid protection for the safety of urban low airspace.
CytoNiche
Series B in 2022
CytoNiche is engaged in the development of 3D micro-organization engineering technology, primarily for stem cell research. The company utilizes technology derived from Tsinghua University to create innovative solutions such as automated and intelligent stem cell culture amplification processes. Its offerings include high-quality stem cell cultures, injectable 3D micro-tissue treatments, and 3D drug screening microcarriers, which facilitate extensive drug screening operations. CytoNiche aims to provide reliable 3D micro-tissue products and services tailored for research institutes, clinical organizations, stem cell companies, and drug research enterprises, thereby advancing the capabilities in stem cell research and drug development.
InnoStar Semiconductor
Series A in 2022
InnoStar Semiconductor specializes in developing and providing advanced semiconductor storage solutions, particularly focusing on resistive random access memory (ReRam) technology. This innovative approach offers high performance and low power consumption, catering to various industries including information security, Internet of Things (IoT), artificial intelligence (AI), and cloud computing. By commercializing ReRam memory chips, InnoStar aims to enhance storage capabilities and intelligent computing, setting new industry standards while addressing the growing demands for efficient data processing and storage solutions.
Xgene Pharmaceutical
Series C in 2021
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.
Walnut Computer Technology
Series A in 2021
Walnut Computer Technologies develops, markets, and provides associated services for medical software and hardware. They serve software that manages medical data, medical records, and medical imaging data by utilizing cloud computing technology, enabling medical institutions.
ChosenMed
Series C in 2021
ChosenMed is a healthcare company specializing in oncology precision medicine. It is dedicated to early tumor screening and companion diagnosis, aiming to improve patient outcomes in cancer care. The company develops products that address the early screening, prevention, and diagnosis of tumors. Additionally, ChosenMed provides guidance for targeted medication related to solid tumors and predicts the efficacy of tumor immunotherapy. By offering a comprehensive range of precision medical solutions and immunotherapy options, ChosenMed strives to enhance treatment effectiveness and support personalized patient care in oncology.
Immunophage Biotech
Series A in 2021
Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.
Yizhun Intelligent
Series C in 2021
Yizhun AI is an artificial intelligence and robotics company focused on developing advanced medical imaging technology. Its primary objective is to enhance the detection of nodules and tumors in the lungs and mammary glands. By leveraging artificial intelligence, Yizhun AI's technology significantly accelerates the identification of malignant entities, thereby assisting healthcare professionals in making accurate diagnoses. Through its innovative solutions, the company aims to improve patient outcomes and streamline the diagnostic process in the medical field.
Kangpu Biopharmaceuticals
Series B in 2021
Kangpu Biopharmaceuticals is a clinical-stage company dedicated to the discovery and development of small molecule drugs aimed at treating cancer, autoimmune diseases, and inflammatory disorders. The company leverages proprietary technologies that focus on the modulation of ubiquitin-protein interactions to create innovative medical treatments. Additionally, Kangpu employs a drug discovery platform known as X-Synergy®, which enhances its capabilities in developing targeted therapies. By utilizing novel approaches such as targeted protein ubiquitination and degradation, Kangpu aims to deliver effective medical solutions that improve patient health outcomes.
Tasogare
Series B in 2021
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.
Biren Technology
Series B in 2021
Biren Technology is a high-tech startup specializing in the design and development of intelligent processors tailored for GPU and DSA computation architectures. The company focuses on creating integrated software and hardware platforms that support intelligent computing applications, including cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing. With a dedicated team of industry experts and elite engineers, Biren Technology aims to deliver versatile computing solutions that blend general computing capabilities with specific applications. Its research division is committed to advancing key technologies in intelligent computing systems, emphasizing new architectures and advanced compilation techniques, thereby facilitating technological breakthroughs in various high-tech sectors.
Artivila Therapeutics
Seed Round in 2021
Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.
Keythera Pharmaceuticals
Series A in 2021
Keythera Pharmaceuticals is engaged in the development of small molecule drugs, focusing on innovative therapeutics aimed at addressing unmet medical needs both in China and globally. The company specializes in researching and developing novel medications specifically targeting autoimmune and tumor diseases. Through its biomedical platforms, Keythera Pharmaceuticals seeks to provide improved treatment options for patients suffering from these conditions.
OriCell Therapeutics
Series A in 2021
OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Raynovent
Series B in 2020
Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.
Zhiketong Technology
Series D in 2020
Beijing Zhiketong Technology Co., Ltd., established in 2014, specializes in providing direct marketing services for the hospitality, leisure, and entertainment sectors through its web platform on WeChat. The company acts as an agency that offers a range of digital marketing solutions, including consulting, advertising, and comprehensive data analysis. By assisting partners in optimizing their management efficiency and enhancing service quality, Zhiketong Technology helps businesses increase brand awareness and attract more customers. Its services encompass intelligent data analysis systems, online marketing strategies, customer management tools, and online store design, all aimed at driving revenue growth for hotels and tourism attractions in China.
Leto Laboratories
Series B in 2020
Leto Laboratories focuses on research and development in the field of protein re-engineering, aiming to address gaps in the treatment of cancer and rare diseases. The company employs advanced technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms. By leveraging these innovative approaches, Leto Laboratories strives to create more effective protein-based therapies, enhancing treatment options for patients. The diverse research team works collaboratively to advance the company's mission of improving healthcare outcomes through specialized protein technology.
etherna immunotherapies
Series B in 2020
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.
independence Day
Series B in 2019
Independence Day is an internet platform that matches companies' needs with available spare time to provide employment services. In order to address businesses' temporary employment needs, they offer jobs to blue-collar workers and college students. It is a service platform that is offline.
Yidebang
Series B in 2019
Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.
EO Company
Series C in 2019
EO Company is a technology and industry innovation service platform that specializes in the large health sector. Its core offerings include health technology media, industry business conferences, and research consultations. Targeting the business end of the health industry, EO Company provides a range of online products such as industry content planning, video columns, and consulting services. The platform is designed to facilitate connections within the industry chain and offers insights backed by high market attention and an international perspective. By focusing on technological and industrial innovation, EO Company aims to support the advancement of the health sector in China.
Shanutec
Series B in 2018
Shanutec is a developer of smart household equipment and applications, focusing on enhancing domestic living through innovative technology. The company specializes in creating smart home systems and appliances, including electrical wiring solutions for both residential and commercial spaces. Shanutec offers a range of products such as power tracks with removable electric sockets, energy management systems, and environmental and safety systems. These offerings enable homeowners to easily install and manage smart appliances, ultimately contributing to a more comfortable and efficient living environment.
EO Company
Series B in 2018
EO Company is a technology and industry innovation service platform that specializes in the large health sector. Its core offerings include health technology media, industry business conferences, and research consultations. Targeting the business end of the health industry, EO Company provides a range of online products such as industry content planning, video columns, and consulting services. The platform is designed to facilitate connections within the industry chain and offers insights backed by high market attention and an international perspective. By focusing on technological and industrial innovation, EO Company aims to support the advancement of the health sector in China.
Veritas Genetics
Venture Round in 2018
Veritas Genetics International Ltd. is a genetic testing service provider based in Danvers, Massachusetts, with operations across North America, Asia, and Europe. The company collaborates with scientists, physicians, advisors, and patient advocates to develop and deliver innovative genetic testing solutions. Veritas Genetics utilizes advanced genetic technology that can identify a broader spectrum of gene variations than conventional next-generation sequencing methods. Among its offerings, the company provides a screening test for hereditary breast and ovarian cancer risk, facilitating informed decision-making for clinical researchers and healthcare providers. Through its services, Veritas Genetics aims to empower individuals to lead healthier and longer lives.
EO Company
Series B in 2017
EO Company is a technology and industry innovation service platform that specializes in the large health sector. Its core offerings include health technology media, industry business conferences, and research consultations. Targeting the business end of the health industry, EO Company provides a range of online products such as industry content planning, video columns, and consulting services. The platform is designed to facilitate connections within the industry chain and offers insights backed by high market attention and an international perspective. By focusing on technological and industrial innovation, EO Company aims to support the advancement of the health sector in China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.